12:37
MYND Life Sciences CEO Dr. Lyle Oberg said His Team Has Found The Switch For Depression
The Dales Report
18:18
Why iSTRYM And Our Tech-First Approach Makes More Sense Than A Clinic Model
26:19
CEO Daniel Cohen on Pharmadrug Updates: DMT Research, THC Oil, Mushrooms
19:43
Mydecine COO Damon Michaels on Canada Cultivation and Mushroom Editing
8:29
Microdosing, PTSD and Research: Mydecine COO Damon Michaels Talks Psychedelics
15:32
What Is A Compassionate Access Trial? Numinus CSO & Founder Stacey Wallin Has The Details
13:41
Tryp Therapeutics To Benefit Should California Implement Bill To Legalize Psychedelics Possession
17:54
Psychedelic Retreats More in Alignment with Ancestors: Jesse Hanson, PhD, HOLOS
23:16
Getting People to Help Changes Everything: William Cook, CEO of MindLeap
7:34
‘Small Pharma Was Established to Make Medicine’ – Peter Rands, Director and CEO
21:52
CEO Daniel Cohen on COVID, Cancer, Cepharanthine, and More for PharmaDrug
13:16
Newest Numinus Production Process Has “The Potential To Transform The Sector”
15:11
CEO Kelsey Ramsden of MINDCURE Talks About iSTRYM Platform
14:30
MYND Life Sciences Working On Truly Novel Research For Depressive And Neurological Diseases
17:43
NeonMind CEO Rob Tessarolo on Company Branded Clinics: The First Could Be 2022
19:07
Red Light Holland CEO Todd Shapiro Speaks on Bruce Linton and The HighBrid Lab
14:20
Not a One Trick Pony: Revive Therapeutics COO Derrick Welsh Shares Antigua Updates
10:30
Is A NASDAQ Listing In The Future For Numinus?
20:06
Psybio Therapeutics CEO Evan Levine Comments On Maxim Group Buy Rating, European Research, And More
9:40
Peter Rands, CEO of Small Pharma, on DMT and Parliament
14:22
Mydecine CEO Josh Bartch Speaks on Psilocybin and Smoking Cessation
11:38
MINDCURE CEO Kelsey Ramsden on Exciting Ibogaine Synthesis Patent News
13:30
MYND Life CEO Dr. Oberg on Depression Biomarker: We’ll See Revenue in ‘22
12:58
Tryp Therapeutics CEO Greg McKee: “About Ready” To Initiate Two Phase 2A Studies
20:03
Daniel Cohen, Pharmadrug CEO, Weighs in With Updates on Cepharanthine
14:39
Mydecine CSO Rob Roscow: MDMA and Psychedelics Have More Opportunities Than Cannabis
12:55
Numinus Maps Out Cure For PTSD With Open Label Study
16:59
CEO Rob Tessarolo Explains NeonMind Reorganization and Goals With FDA
11:10
Why DMT Could Be More Effective Than Psilocybin
13:04
COO Damon Michaels On Mydecine’s Collaboration With Johns Hopkins University
11:35
PharmaDrug CEO Daniel Cohen On Johns Hopkins University Partnership to Evaluate DMT - PT 1
12:52
PharmaDrug's JHU Partnership To Study DMT, Psychedelics, And The Future Of The Industry - Pt 2
7:52
Mydecine Signs Agreement With John Hopkins University
17:50
Mindcure CEO: iSTRYM & Psychedelic Operational Clinics
13:26
MYND Life Sciences Biomarkers: A Cure For Alzheimer?
25:43
How Psychedelics Will Change the Health Care Landscape
17:22
Numinus Inc.CEO Talks NASDAQ Ambitions
